Figures & data
Figure 1 Flow chart illustrating the participation of patients who had an OAT installed at discharge from the stroke unit after stroke or transient ischemic attack.
Abbreviation: OAT, oral anticoagulant therapy.
![Figure 1 Flow chart illustrating the participation of patients who had an OAT installed at discharge from the stroke unit after stroke or transient ischemic attack.](/cms/asset/33d8860a-dbb0-4509-962f-aaa295c48b51/dppa_a_88994_f0001_b.jpg)
Figure 2 Global neurological function of the patients at 1-year follow-up.
![Figure 2 Global neurological function of the patients at 1-year follow-up.](/cms/asset/8d8ba1a0-afb4-400f-9fa1-1a6a2f9cdcce/dppa_a_88994_f0002_c.jpg)
Table 1 Demographic characterization of patients’ anticoagulated with VKA or NOAC at discharge from our stroke units
Table 2 Persistence to OAT at 1 year by specific choice of OAT at discharge
Figure 3 Patients’ self-reported adherence assessed with the MMAS-8.
Abbreviations: MMAS-8, eight-point Morisky Medication Adherence Scale; VKA, vitamin K antagonists.
![Figure 3 Patients’ self-reported adherence assessed with the MMAS-8.](/cms/asset/ea83f232-ae26-4deb-ab9f-fa8377d5db27/dppa_a_88994_f0003_c.jpg)
Figure 4 Multivariate analysis of factors influencing adherence to OAT in stroke patients.
Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulants; mRS, modified Ranking Scale score; OAT, oral anticoagulant therapy; OR, odds ratio; VKA, vitamin K antagonists.
![Figure 4 Multivariate analysis of factors influencing adherence to OAT in stroke patients.](/cms/asset/05095222-0994-4f77-a358-cf5421ff958a/dppa_a_88994_f0004_b.jpg)
Table 3 Univariate comparison of patient characteristics between persistent and nonpersistent patients
Table S1 Demographic characterization by specific choice of OAT
Table S2 Reasons to switch therapy during the 1-year follow-up period